Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide

Eur Neuropsychopharmacol. 2013 Dec;23(12):1769-78. doi: 10.1016/j.euroneuro.2013.01.008. Epub 2013 Feb 20.

Abstract

Activation of purinergic receptors by ATP (P2R) modulates glutamate release and the activation of post-synaptic P2R is speculated to induce nitric oxide (NO) synthesis. Increased glutamatergic and nitrergic signaling have been involved in the neurobiology of stress-related psychiatric disorders such as anxiety and depression. Therefore, the aim of this study was to test the effects of two P2R antagonists (PPADS and iso-PPADS) in animals submitted to models predictive of antidepressant-, anxiolytic- and anticompulsive-like effects. Swiss mice receiving PPADS at 12.5mg/kg showed reduced immobility time in the forced swimming test (FST) similarly to the prototype antidepressant imipramine (30mg/kg). This dose was also able to decrease the number of buried marbles in the marble-burying test (MBT), an anticompulsive-like effect. However, no effect was observed in animals submitted to the elevated plus maze (EPM) and to the open field test. The systemic administration of iso-PPADS, a preferential P2XR antagonist, also reduced the immobility time in FST, which was associated to a decrease in NOx levels in the prefrontal cortex. In addition, P2X7 receptor was found co-immunoprecipitated with neuronal nitric oxide synthase (NOS1) in the prefrontal cortex. These results suggest that P2X7, possibly coupled to NOS1, could modulate behavioral responses associated to stress-related disorders and it could be a new target for the development of more effective treatments for affective disorders.

Keywords: Forced swimming test; Marble burying; P2 receptor; PPADS; Purinergic system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / therapeutic use*
  • Brain / drug effects
  • Brain / metabolism
  • Compulsive Behavior / drug therapy*
  • Depression / drug therapy*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Exploratory Behavior / drug effects
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Immobility Response, Tonic / drug effects
  • Immobility Response, Tonic / physiology
  • Male
  • Maze Learning / drug effects
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type II / metabolism
  • Paroxetine / pharmacology
  • Paroxetine / therapeutic use
  • Purinergic Antagonists / pharmacology
  • Purinergic Antagonists / therapeutic use*
  • Pyridoxal Phosphate / analogs & derivatives
  • Pyridoxal Phosphate / pharmacology
  • Pyridoxal Phosphate / therapeutic use
  • Rats
  • Receptors, Purinergic / metabolism
  • Swimming / psychology

Substances

  • Antidepressive Agents
  • Purinergic Antagonists
  • Receptors, Purinergic
  • pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
  • Nitric Oxide
  • Paroxetine
  • Pyridoxal Phosphate
  • Nitric Oxide Synthase Type II